Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793398 | 0.85 | PANK3 (0.37) | PANK3KDM4EPOLBALDH1A1SMO | |
| SCHEMBL19145349 | 0.81 | SLC6A9 (0.43) | AOC3ACHEKDM4EOPRM1OPRL1 | |
| SCHEMBL3323407 | 0.77 | KDM4E (0.43) | PANK3KDM4EPOLBALDH1A1SMO | |
| SCHEMBL1433020 | 0.77 | ALDH1A1 (0.47) | PANK3KDM4EPOLBALDH1A1SMO | |
| SCHEMBL31370545 | 0.77 | AKR1C3 (0.51) | PANK3KDM4EOPRM1OPRL1ALDH1A1 | |
| SCHEMBL18186155 | 0.77 | POLB (0.63) | AOC3ACHEKDM4EOPRM1OPRL1 | |
| SCHEMBL15205930 | 0.77 | AKR1C3 (0.51) | PANK3KDM4EOPRM1OPRL1ALDH1A1 | |
| SCHEMBL19105540 | 0.77 | PANK3 (0.39) | PANK3AOC3ACHEKDM4EOPRM1 | |
| SCHEMBL20424636 | 0.76 | POLB (0.42) | AOC3ACHEOPRM1OPRL1POLB | |
| SCHEMBL1852499 | 0.76 | HTR3A (0.50) | PANK3KDM4EALDH1A1SMOCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| WO-2018138359-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| EP-2634176-A1 | PYRIDINE DERIVATIVE AND MEDICINAL AGENT | Nippon Shinyaku Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NIPPON SHINYAKU CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2479165-A1 | GLYCINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034078-A1 | GLYCINE COMPOUND | アステラス製薬株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| CN-1326838-C | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | PANK3 2976/4885AOC3 894/4885ACHE 4442/4885 |
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NR0B2, NR0B1, CNKSR1 | PANK3 3845/4885AOC3 1570/4885ACHE 2562/4885 |
| US-11077115-B2 | Rorgamma modulators and uses thereof | RORB, RORC, RORA | PANK3 2632/4885AOC3 4755/4885ACHE 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.